CDK1 and ovarian cancer: Despite advances in surgical techniques and chemotherapeutic agents, the five-year survival rate for advanced-stage ovarian cancer remains below 30%, highlighting the urgent need for novel therapeutic strategies targeting key molecular drivers like CDK1 [15].